Profile data is unavailable for this security.
About the company
Shanghai Henlius Biotech Inc. is a China-based company principally involved in the research, development, production and sales of monoclonal antibody products. The Company’s main products include rituximab injection HLX01 (Hanlikang), Herceptin (trastuzumab) biosimilar HLX02, Humira (adalimumab) biosimilar HLX03 and Avastin (bevacizumab) biosimilar HLX04, as well as bio-innovative drug candidates, including HLX06 (a novel VEGFR2 inhibitor), HLX07 (an EGFR inhibitor), HLX10 (a novel PD-1 inhibitor), HLX20 (a novel PD-L1 inhibitor) and HLX22 (a novel HER2 inhibitor), among others. The Company is also engaged in the provision of related technical services. The Company operates its businesses primarily in Mainland China and the United States.
- Revenue in HKD (TTM)6.19bn
- Net income in HKD759.89m
- Incorporated2010
- Employees3.55k
- LocationShanghai Henlius Biotech Inc11/F, B8 Building, No. 188 Yizhou Road,SHANGHAI 200233ChinaCHN
- Fax+86 2 134611802
- Websitehttps://www.henlius.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tong Ren Tang Technologies Co Ltd | 7.55bn | 714.29m | 7.15bn | 4.01k | 10.01 | 0.9177 | 5.00 | 0.9468 | 0.5577 | 0.5577 | 5.89 | 6.08 | 0.5026 | 0.9881 | 5.22 | 1,840,563.00 | 7.42 | 7.68 | 11.69 | 12.32 | 40.97 | 43.50 | 14.76 | 16.11 | 2.30 | -- | 0.1968 | 39.94 | 13.04 | 6.01 | 1.25 | -2.73 | -22.26 | -0.0089 |
| Beijing Tong Ren Tang Chinese Medicine | 1.38bn | 494.14m | 7.43bn | 779.00 | 15.03 | 1.95 | 12.01 | 5.39 | 0.5903 | 0.5903 | 1.64 | 4.55 | 0.3284 | 0.3554 | 3.62 | 1,725,133.00 | 12.72 | 16.71 | 14.09 | 18.75 | 72.06 | 69.88 | 38.72 | 40.72 | 9.55 | -- | 0.0327 | 68.87 | -11.91 | 0.1459 | -16.33 | -1.43 | -16.30 | 7.49 |
| Yichang Hec Changjiang Pharmactcl Co Ltd | 6.08bn | 1.81bn | 7.74bn | 4.89k | 4.28 | 0.8142 | 3.69 | 1.27 | 2.06 | 2.06 | 6.91 | 10.81 | 0.4272 | 2.50 | 3.74 | 1,316,787.00 | 11.69 | 8.03 | 17.27 | 11.81 | 78.90 | 79.97 | 27.37 | 20.80 | 1.93 | 50.79 | 0.2126 | 15.81 | 68.08 | 20.18 | 2,501.24 | 16.15 | -11.50 | -- |
| Shanghai Fudan-Zhangjiang Bio-Pharm. Co | 807.84m | 121.46m | 7.82bn | 948.00 | 24.46 | 1.13 | -- | 9.68 | 0.1153 | 0.1153 | 0.7595 | 2.50 | 0.2504 | 1.26 | 1.35 | 852,156.30 | 3.75 | 7.03 | 4.66 | 9.05 | 91.25 | 92.17 | 14.97 | 17.26 | 3.78 | -- | 0.0052 | 39.16 | -17.50 | 2.78 | -21.28 | -0.6326 | 20.49 | -- |
| China Shineway Pharmaceutical Group Ltd | 4.61bn | 1.21bn | 8.05bn | 3.23k | 6.07 | 1.00 | 5.80 | 1.75 | 1.60 | 1.60 | 6.11 | 9.74 | 0.4476 | 1.28 | 5.26 | 1,343,072.00 | 11.76 | 8.03 | 15.47 | 9.77 | 75.21 | 74.55 | 26.27 | 17.87 | 3.14 | -- | 0.0457 | 36.29 | 14.32 | 11.94 | 34.14 | 13.89 | 0.6396 | 12.88 |
| AIM Vaccine Co Ltd | 1.30bn | -1.31bn | 8.13bn | 1.56k | -- | 2.11 | -- | 6.25 | -1.08 | -1.08 | 1.07 | 3.18 | 0.1462 | 0.6325 | 1.10 | 800,318.30 | -22.69 | -- | -37.16 | -- | 72.34 | -- | -155.22 | -- | 0.6836 | -6.61 | 0.3437 | -- | -6.06 | -- | -307.07 | -- | -- | -- |
| Everest Medicines Ltd | 459.39m | -1.16bn | 8.28bn | 520.00 | -- | 1.69 | -- | 18.02 | -3.59 | -3.59 | 1.42 | 15.09 | 0.0756 | 5.23 | 3.22 | 1,063,409.00 | -19.03 | -30.52 | -20.21 | -33.14 | 75.74 | -- | -251.64 | -5,745.25 | 4.62 | -- | 0.1119 | -- | 884.46 | -- | -241.50 | -- | 4.65 | -- |
| Cansino Biologics Inc | 668.99m | -951.24m | 10.69bn | 1.49k | -- | 1.16 | -- | 15.97 | -3.85 | -3.85 | 2.71 | 22.48 | 0.0676 | 1.28 | 0.8385 | 447,782.40 | -10.15 | -4.27 | -13.73 | -5.60 | 14.38 | -- | -150.19 | -27.72 | 2.19 | -- | 0.3028 | -- | -66.52 | 213.94 | -63.04 | -- | 30.60 | -- |
| Luye Pharma Group Ltd | 6.93bn | 845.64m | 12.30bn | 5.23k | 14.55 | 0.8608 | 7.23 | 1.78 | 0.2248 | 0.2248 | 1.84 | 3.80 | 0.236 | 2.44 | 3.02 | 1,314,909.00 | 3.11 | 2.80 | 5.47 | 4.45 | 68.73 | 70.53 | 13.18 | 10.39 | 1.20 | 3.14 | 0.4103 | 11.82 | 2.70 | 3.50 | -11.94 | -16.39 | -14.05 | -- |
| Shanghai Henlius Biotech Inc | 6.19bn | 759.89m | 12.36bn | 3.55k | 16.31 | 4.37 | 10.61 | 2.00 | 1.39 | 1.39 | 11.34 | 5.21 | 0.5764 | 1.90 | 6.82 | 1,702,200.00 | 7.07 | -8.59 | 14.25 | -14.14 | 73.23 | 71.77 | 12.27 | -27.37 | 0.329 | 7.60 | 0.6113 | -- | 67.82 | 273.51 | 178.53 | -- | 49.14 | -- |
| SSY Group Ltd | 6.47bn | 1.37bn | 12.42bn | 5.80k | 9.14 | 1.72 | 6.79 | 1.92 | 0.4593 | 0.4593 | 2.18 | 2.44 | 0.5418 | 2.75 | 3.07 | 1,155,141.00 | 11.54 | 10.51 | 14.88 | 14.03 | 54.39 | 58.72 | 21.30 | 18.62 | 2.06 | 28.65 | 0.323 | 38.56 | 0.4505 | 9.10 | 17.44 | 7.66 | 3.94 | 13.56 |
| 3SBio Inc | 9.24bn | 1.82bn | 16.31bn | 5.61k | 9.11 | 1.03 | 7.22 | 1.76 | 0.7473 | 0.7473 | 3.79 | 6.59 | 0.3575 | 1.52 | 6.87 | 1,708,233.00 | 7.25 | 7.44 | 10.26 | 9.29 | 85.94 | 82.91 | 20.27 | 21.50 | 1.57 | 141.55 | 0.1998 | -- | 13.84 | 11.26 | -19.13 | 3.94 | 8.78 | -- |
| Simcere Pharmaceutical Group Ltd | 6.96bn | -1.21bn | 16.68bn | 6.41k | -- | 2.21 | -- | 2.40 | -0.4626 | -0.4626 | 2.70 | 2.98 | 0.5198 | 2.19 | 2.64 | 990,578.20 | -9.04 | 10.17 | -11.71 | 15.60 | 77.02 | 78.82 | -17.40 | 17.50 | 1.88 | 0.4721 | 0.1461 | 46.68 | 4.49 | 7.92 | -23.22 | -0.5213 | 23.93 | -- |
| Grand Pharmaceutical Group Ltd | 10.59bn | 2.41bn | 17.82bn | 10.78k | 7.29 | 1.13 | 6.20 | 1.68 | 0.6885 | 0.6885 | 3.03 | 4.43 | 0.4472 | 3.62 | 4.54 | 1,005,064.00 | 10.25 | 10.09 | 14.21 | 14.01 | 59.00 | 61.97 | 22.92 | 22.35 | 1.09 | -- | 0.2232 | 26.94 | 10.12 | 12.06 | -9.59 | 21.41 | 5.69 | 24.77 |
Data as of Oct 10 2024. Currency figures normalised to Shanghai Henlius Biotech Inc's reporting currency: Hong Kong Dollar HKD
7.96%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| UBS Asset Management Switzerland AGas of 25 Jul 2024 | 10.79m | 6.60% |
| Qatar Investment Authority (Investment Management)as of 09 May 2024 | 1.68m | 1.03% |
| SSgA Funds Management, Inc.as of 03 Jul 2024 | 152.90k | 0.09% |
| China Universal Asset Management Co., Ltd.as of 31 Dec 2023 | 131.40k | 0.08% |
| Dimensional Fund Advisors LPas of 04 Jul 2024 | 127.90k | 0.08% |
| ICBC Credit Suisse Asset Management Co., Ltd.as of 31 Dec 2023 | 90.00k | 0.06% |
| DFA Australia Ltd.as of 30 Jun 2024 | 13.31k | 0.01% |
| Dimensional Fund Advisors Ltd.as of 31 May 2024 | 10.09k | 0.01% |
| Mackenzie Investments Corp. (United States)as of 31 May 2024 | 6.33k | 0.00% |
| Mackenzie Financial Corp.as of 30 Sep 2023 | 3.96k | 0.00% |
More ▼
Data from 31 Dec 2023 - 01 Jul 2024Source: FactSet Research Systems Inc.
